![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PREX2 |
Gene summary for PREX2 |
![]() |
Gene information | Species | Human | Gene symbol | PREX2 | Gene ID | 80243 |
Gene name | phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2 | |
Gene Alias | DEP.2 | |
Cytomap | 8q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q70Z35 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80243 | PREX2 | ATC13 | Human | Thyroid | ATC | 1.13e-15 | 5.04e-01 | 0.34 |
80243 | PREX2 | ATC5 | Human | Thyroid | ATC | 1.22e-20 | 5.40e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016358110 | Thyroid | ATC | dendrite development | 119/6293 | 243/18723 | 4.65e-07 | 6.75e-06 | 119 |
GO:005105618 | Thyroid | ATC | regulation of small GTPase mediated signal transduction | 141/6293 | 302/18723 | 1.43e-06 | 1.77e-05 | 141 |
GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PREX2 | SNV | Missense_Mutation | c.3716N>A | p.Phe1239Tyr | p.F1239Y | Q70Z35 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
PREX2 | SNV | Missense_Mutation | c.2576N>A | p.Ser859Asn | p.S859N | Q70Z35 | protein_coding | tolerated(0.24) | benign(0) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
PREX2 | SNV | Missense_Mutation | novel | c.1930G>A | p.Val644Ile | p.V644I | Q70Z35 | protein_coding | deleterious(0.05) | benign(0.222) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PREX2 | SNV | Missense_Mutation | novel | c.3073N>G | p.Ile1025Val | p.I1025V | Q70Z35 | protein_coding | tolerated(0.13) | benign(0) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
PREX2 | SNV | Missense_Mutation | c.3305N>C | p.Ile1102Thr | p.I1102T | Q70Z35 | protein_coding | tolerated_low_confidence(0.09) | benign(0.007) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PREX2 | SNV | Missense_Mutation | rs751712561 | c.1088G>A | p.Arg363Gln | p.R363Q | Q70Z35 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |
PREX2 | SNV | Missense_Mutation | novel | c.2195A>C | p.His732Pro | p.H732P | Q70Z35 | protein_coding | deleterious(0.03) | possibly_damaging(0.734) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
PREX2 | SNV | Missense_Mutation | c.4609N>T | p.Thr1537Ser | p.T1537S | Q70Z35 | protein_coding | deleterious(0.05) | possibly_damaging(0.751) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PREX2 | SNV | Missense_Mutation | c.4535N>T | p.Ser1512Leu | p.S1512L | Q70Z35 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PREX2 | SNV | Missense_Mutation | c.2714N>C | p.Lys905Thr | p.K905T | Q70Z35 | protein_coding | deleterious(0.01) | benign(0.031) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
80243 | PREX2 | KINASE, CLINICALLY ACTIONABLE, DRUG RESISTANCE | VEMURAFENIB | VEMURAFENIB | 24265155 |
Page: 1 |